Literature DB >> 7652494

Breast cancer and clinical utility of CA 15-3 and CEA.

W Jäger1, S Krämer, V Palapelas, L Norbert.   

Abstract

This manuscript summarizes the experiences with CA 15-3 and CEA obtained in 8,000 breast cancer patients. These markers were usually in normal range (CEA < 6 micrograms/L, CA 15-3 < 40 U/L) before surgery and increased only before the development of distant metastases. 80% of all patients with metastases had elevated marker levels several months before or at the time of detection of metastases. Therefore CA 15-3 and CEA determinations should be used as an easy method for screening of metastases during follow-up of breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7652494     DOI: 10.3109/00365519509090570

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest Suppl        ISSN: 0085-591X


  3 in total

1.  Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer.

Authors:  Vandana G Abramson; Ingrid A Mayer
Journal:  Curr Treat Options Oncol       Date:  2011-12

2.  Reproductive Factors, Steroid Receptor Status, and Tumour Markers of HER2-Positive Breast Cancer in Northern China.

Authors:  Xiaoyan Yuan; Xuezhen Song; Min Jiang; Qiujing Li; Xiaodan Liu; Mingyi Wang
Journal:  Breast Care (Basel)       Date:  2009-09-21       Impact factor: 2.860

3.  Prognostic Value of Preoperative Serum Levels of Periostin (PN) in Early Breast Cancer (BCa).

Authors:  Pier Vitale Nuzzo; Alessandra Rubagotti; Francesca Argellati; Antonio Di Meglio; Elisa Zanardi; Linda Zinoli; Paola Comite; Michele Mussap; Francesco Boccardo
Journal:  Int J Mol Sci       Date:  2015-07-28       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.